Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5780 - Antitumor activity, immunogenicity and safety of a novel PD-1 vaccine in combination with two chimeric HER-2 peptide vaccine in syngeneic Balb/c, C57Bl/6 models and in beagle dogs


30 Sep 2019


Poster Display session 3



Tumour Site


Pravin Kaumaya


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


P.T..P. Kaumaya1, J. Overholser2, L. Guo2, Y. Yang3, M. Penichet4, B. Sayanjali2, N. Ede5, L. Chong6, T. Bekaii-Saab7

Author affiliations

  • 1 Ob/gyn; James Comprehensive Cancer Center, Ohio State University Medical Center, 43210 - Columbus/US
  • 2 Ob/gyn, The Ohio State University Medical Center, 43210 - Columbus/US
  • 3 Neurology, The Ohio State University Medical Center, 43210 - Columbus/US
  • 4 Medicine, UCLA, 90095 - Los Angeles/US
  • 5 Technology, Imugene, 3053 - Carlton/AU
  • 6 Imugene, Imugene, Sydney/AU
  • 7 Medical Oncology, Mayo Clinic Cancer Center, 85054 - Phoenix/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5780


Anti-PD-1 blocking monoclonal antibodies (mAbs) such as nivolumab or pembrolizumab have shown potent anti-tumor effects in different metastatic cancers. Similarly, anti-HER-2 mAbs such as Herceptin and Perjeta are approved for breast cancer. These mAbs are only effective in 10-25% of cancer patients, and are limited by high costs, side effects and development of resistance. Contrary to treatment with monoclonal antibodies, chimeric B-cell cancer vaccines incorporating a “promiscuous” T cell epitope have the advantage of safer and cheaper alternatives, producing a specific immune response that induces memory B & T cell responses, while reducing immune evasion, suppression and resistance.


We have translated two HER-2 combination peptide vaccines (B-Vaxx) to the clinic in a Phase 1/2b trial to safely deliver curative and transformative cancer immunotherapies to advanced cancer patients. We have created and established the development of a novel B-cell peptide vaccine (Key-Vaxx) with high immunogenicity that binds to human PD-1 and produces tumor inhibition in vivo in two animal models of colon cancer. We will describe the CT-26, CT26-HER2 and MC38 tumor models in Balb/c and C57/Bl6 used to test for synergistic effects of anti-PD1 immunization therapy in combination with anti-HER2 immunization therapy. The immunogenicity/optimal immunologic dose and toxicity profile was investigated in beagle dogs.


We show robust HER-2 and PD-1 antibody responses in mice, beagle dogs and non-human primates. The individual (PD-1) or combined vaccination (B-Vaxx)) was effective in reducing tumor growth in a Balb/c and C57Bl/6 syngeneic model of colon carcinoma and exhibited superior activity compared to the positive gold control anti-mouse PD-1 (CD279) monoclonal antibody.


Development of PD-1 B-cell vaccine was successful, showing no evidence of toxicity or autoimmunity in mice, rabbits and beagle dogs. The combination vaccines could provide improved outcomes in early stage disease sparing patients the toxicity of chemotherapy. A phase 1 clinical trial with the PD-1 vaccine is under planning.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


NIH; Imugene.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.